Intersect ENT Announces FDA Submission to Seek Expanded Indication of PROPEL Mini Steroid Releasing Implant to Treat Patients With Frontal Sinus Disease

MENLO PARK, Calif.-- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the company has submitted a supplemental premarket approval (PMA-s) submission to the U.S. Food and Drug Administration (FDA) to seek approval to expand the indication of the PROPEL^® mini steroid releasing sinus implant to the treatment of patients undergoing frontal sinus surgery.

An expanded indication would allow Intersect ENT to market placement of PROPEL mini in the frontal sinuses, which are located behind the eyebrows. PROPEL mini is currently indicated for placement in the ethmoid sinuses, located just behind the bridge of the nose.

EDAP Reports Growing Momentum in Europe for HIFU Treatment of Prostate Cancer

• Live Focal One HIFU treatment at Robotic Urology Congress, Bilbao, Spain
• Strong participation in German Urology Society Congress
• Dedicated Intensive training program being implemented following purchase of Focal One by private group of Hospitals in France

LYON, France, Sept. 24, 2015 -- EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, today provided an update on the growing momentum being experienced by HIFU technology in the European market, in particular the rapidly increasing interest in the use of focal therapy in the treatment of prostate cancer.

Valeant Pharmaceuticals To Acquire Synergetics USA

LAVAL, Quebec, Sept. 2, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its affiliate has entered into a definitive agreement under which Valeant will acquire Synergetics USA, Inc. (NASDAQ:SURG ) for $6.50 per share in cash. In addition to the upfront cash payment, Synergetics stockholders will receive additional cash payments of up to $1.00 per share if specified sales milestones are achieved following the closing.  The transaction is expected to close in the fourth quarter of 2015 and is subject to customary closing conditions and regulatory approvals.

"The addition of Synergetics' portfolio of instruments and devices will further enhance Bausch + Lomb's presence around the world in the rapidly evolving field of vitreoretinal surgery," stated J. Michael Pearson, chairman and chief executive officer of Valeant.  "We are committed to delivering a valuable and broad array of surgical devices and instruments to serve the needs of the surgical retina community and their patients."

Stereotaxis Awarded U.S. Patent Covering Transmission of Data for Odyssey(R) Solutions

ST. LOUIS, Sept. 1, 2015 -- Stereotaxis, Inc. (STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,111,016 to the Company entitled "Management of Live Remote Medical Display." This patent allows for the future development of features within the Odyssey^(R) Information Management Solution that optimize data transmission across a network to a high-resolution display facilitating the management of medical procedures.

"We are pleased to receive this strategic patent, which could variously be applied to data generated when performing many different types of procedures within hospitals," said William C. Mills, Stereotaxis Chief Executive Officer. "As the amount of high-resolution video, imaging, and graphics being transmitted across hospital networks continues to grow, the ability to optimize and manage bandwidth usage becomes increasingly important.